Association between miR-124-1 rs531564 polymorphism and risk of cancer
Loading...
Date
2018-06-28
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Many studies examined the association between miR-124-1 rs531564 polymorphism and the risk of some human
cancers, but the findings remain controversial. This update meta-analysis aimed to validate the association between
rs531564 polymorphism of miR-124-1 and cancer risk. Eligible studies including 6,502 cancer cases and 7,213
controls were documented by searching Web of Science, PubMed, Scopus, and Google scholar databases. Pooled
odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated to quantitatively evaluate the association
between rs531564 variant and cancer risk. The results indicated that rs531564 variant significantly decreased the
risk of cancer in homozygous codominant (OR=0.54, 95 % CI=0.43-0.69, p<0.00001, GG vs CC), dominant
(OR=0.84, 95 % CI=0.72-0.99, p=0.03, CG+GG vs CC), recessive (OR=0.65, 95 % CI=0.54-0.78, p<0.00001,
GG vs CG+CC), and allele (OR=0.84, 95 % CI=0.73-0.96, p=0.008, G vs C) genetic model. Stratified analysis by
cancer type revealed that rs531564 variant was associated with gastric cancer, cervical cancer, esophageal squamous
cell carcinoma and colorectal cancer risk. In summary, the findings of this meta-analysis support an association
between miR-124-1 rs531564 polymorphism and cancer risk. Larger and well-designed studies are required
to estimate this association in detail.
Description
Table of contents
Keywords
miR-124-1, rs531564, Polymorphism, Cancer, Meta-analysis